New MIMS table to guide antihypertensive monitoring in primary care

Monitoring requirements for ACE inhibitors and angiotensin II antagonists are summarised in a new MIMS table.

Monitoring required for patients on ACE inhibitors or angiotensin II antagonists includes renal function and electrolytes. | GETTY IMAGES
Monitoring required for patients on ACE inhibitors or angiotensin II antagonists includes renal function and electrolytes. | GETTY IMAGES

Prescribers can now consult a quick-reference MIMS table for a summary of monitoring requirements for ACE inhibitors and angiotensin II antagonists.

Further information

View ACE inhibitor and angiotensin II antagonist drug recordsMIMS Cardiology Clinic

Covering use of Athe antihypertensives in patients with heart failure, hypertension, chronic kidney disease and following MI, the table summarises the tests needed when starting the drugs, until treatment is stabilised, and subsequently.

Circumstances in which treatment should be stopped are also noted.

Recommendations in the table are summarised from NICE guidelines, CKS and SIGN.

The table is available online and will appear in the forthcoming September quarterly print issue of MIMS.

Other quick-reference drug tables recently added to MIMS include guidance on influenza vaccines for 2020/21 and a comparison of GLP-1 agonists.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

NICE recommends SGLT2 inhibitors for chronic kidney disease

NICE recommends SGLT2 inhibitors for chronic kidney disease

Updated NICE guidance on type II diabetes recommends...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Avoid routinely offering antidepressants for 'less severe' depression, says NICE in draft guidance
Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...